Kondo, Shunsuke http://orcid.org/0000-0001-9565-117X
Iwasa, Satoru
Koyama, Takafumi http://orcid.org/0000-0001-5807-8458
Fujita, Tomoko http://orcid.org/0000-0002-6629-6380
Sugibayashi, Ko http://orcid.org/0000-0003-0285-8054
Murayama, Kosho http://orcid.org/0000-0003-3301-9966
Yamamoto, Noboru http://orcid.org/0000-0002-0787-2851
Funding for this research was provided by:
AstraZeneca K.K.
Article History
Received: 8 March 2022
Accepted: 22 August 2022
First Online: 7 November 2022
Declarations
:
: SK has received research funding from Astellas Pharma Inc., AstraZeneca K.K., AbbVie, Eli Lilly and Company, MSD, Boehringer Ingelheim, and Pfizer. SI has no conflicts of interest to disclose. TK has received honoraria from Sysmex Corporation and research funding from PACT Pharma. TF, KS, and KM are employees of AstraZeneca K.K. NY has provided an advisory role for Eisai, Takeda Pharmaceutical Company, Otsuka Pharmaceutical, Boehringer Ingelheim, CMIC, and Chugai Pharmaceutical Co., Ltd.; received research funding from Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai, Taiho Pharmaceutical, Bristol Myers Squibb, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo Co., Ltd., Bayer, Boehringer Ingelheim, Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company, Ono Pharmaceutical, Janssen Pharma, MSD, Merck, GlaxoSmithKline, Sumitomo Dainippon Pharma, Chiome Bioscience, Otsuka Pharmaceutical, Carna Biosciences, Genmab, and Shionogi; and received honoraria from AstraZeneca K.K., Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical Co., Ltd., Sysmex Corporation, Daiichi Sankyo Co., Ltd., and Eisai.